Collegium Pharmaceutical Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Collegium Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in COLL, but not buy additional shares or sell existing shares.
View analyst ratings for Collegium Pharmaceutical or view top-rated stocks.

Wall Street analysts have given Collegium Pharmaceutical a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Collegium Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Collegium Pharmaceutical.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) released its quarterly earnings data on Thursday, February, 25th. The specialty pharmaceutical company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.29 by $0.09. Collegium Pharmaceutical had a trailing twelve-month return on equity of 12.64% and a net margin of 5.71%.
View Collegium Pharmaceutical's earnings history.

Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, COLL shares have increased by 32.8% and is now trading at $23.33.
View which stocks have been most impacted by COVID-19.

Collegium Pharmaceutical issued an update on its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $330-350 million, compared to the consensus revenue estimate of $337.38 million.

4 analysts have issued 12-month target prices for Collegium Pharmaceutical's shares. Their forecasts range from $8.00 to $34.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 7.2% from the stock's current price.
View analysts' price targets for Collegium Pharmaceutical or view top-rated stocks among Wall Street analysts.

6 employees have rated Collegium Pharmaceutical CEO Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among Collegium Pharmaceutical's employees.

Some companies that are related to Collegium Pharmaceutical include Reata Pharmaceuticals (RETA), Karuna Therapeutics (KRTX), Arvinas (ARVN), Alkermes (ALKS), Pacira BioSciences (PCRX), MorphoSys (MOR), Organogenesis (ORGO), Viela Bio (VIE), OPKO Health (OPK), Taro Pharmaceutical Industries (TARO), Corcept Therapeutics (CORT), Intra-Cellular Therapies (ITCI), ALX Oncology (ALXO), Ligand Pharmaceuticals (LGND) and Global Blood Therapeutics (GBT).
View all of COLL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), (CGC), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends for Collegium Pharmaceutical.

COLL stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Collegium Pharmaceutical or or view top insider-buying stocks.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of COLL stock can currently be purchased for approximately $23.33.

Collegium Pharmaceutical has a market capitalization of $810.86 million and generates $296.70 million in revenue each year. The specialty pharmaceutical company earns $-22,720,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

Collegium Pharmaceutical employs 234 workers across the globe.

The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

Collegium Pharmaceutical is headquartered at 100 Technology Center Drive, Stoughton MA, 02072.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.